Protagenic Therapeutics Inc Financials
This page shows Protagenic Therapeutics Inc (PTIX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Protagenic Therapeutics Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Protagenic Therapeutics Inc generates $0.76 in operating cash flow (-$4.2M OCF vs -$5.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Protagenic Therapeutics Inc generated $0 in revenue in fiscal year 2024.
Protagenic Therapeutics Inc's EBITDA was -$5.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 25.6% from the prior year.
Protagenic Therapeutics Inc reported -$5.5M in net income in fiscal year 2024. This represents a decrease of 10.5% from the prior year.
Protagenic Therapeutics Inc earned $-1.13 per diluted share (EPS) in fiscal year 2024. This represents an increase of 1.7% from the prior year.
Cash & Balance Sheet
Protagenic Therapeutics Inc held $80K in cash against $0 in long-term debt as of fiscal year 2024.
Protagenic Therapeutics Inc had 517,257 shares outstanding in fiscal year 2024. This represents a decrease of 88.3% from the prior year.
Margins & Returns
Capital Allocation
Protagenic Therapeutics Inc invested $3.8M in research and development in fiscal year 2024. This represents an increase of 25.5% from the prior year.
PTIX Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | $0 | $0 | N/A | $0 | $0 |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $154K0.0% | $154K-43.7% | $273K-30.7% | $394K-55.2% | $880K+554.2% | $135K+693.3% | $17K-11.3% | $19K |
| SG&A Expenses | $155K0.0% | $155K-3.2% | $160K-8.7% | $175K-69.1% | $568K+1042.4% | $50K+125.6% | $22K-7.2% | $24K |
| Operating Income | -$925K0.0% | -$925K+16.9% | -$1.1M+52.5% | -$2.3M-61.9% | -$1.4M-260.8% | -$401K-13.0% | -$355K-10.4% | -$322K |
| Interest Expense | $24K0.0% | $24K-30.6% | $34K+114.4% | -$239K | N/A | -$449K-88.0% | -$239K | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | -$3K-200.0% | $3K |
| Net Income | $2.2M0.0% | $2.2M+354.3% | -$869K+82.8% | -$5.1M-251.2% | -$1.4M-69.4% | -$850K-46.0% | -$582K-79.6% | -$324K |
| EPS (Diluted) | $1.140.0% | $1.14+342.6% | $-0.47+65.7% | $-1.37 | $-2.75 | $-0.16 | $-0.11-83.3% | $-0.06 |
PTIX Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $4.4M0.0% | $4.4M-11.4% | $5.0M-22.9% | $6.5M+7182.5% | $89K-95.4% | $2.0M+29.7% | $1.5M+2.8% | $1.5M |
| Current Assets | $2.3M0.0% | $2.3M-19.6% | $2.9M-34.0% | $4.3M+4761.2% | $89K-95.3% | $1.9M+32.3% | $1.4M+3.9% | $1.4M |
| Cash & Equivalents | $15K-99.3% | $2.2M-18.7% | $2.7M-33.5% | $4.1M+28089.3% | $15K-81.7% | $80K+11.4% | $71K-90.0% | $714K |
| Inventory | $1K0.0% | $1K-0.1% | $1K-1.8% | $1K+5.5% | $1K | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $6.8M0.0% | $6.8M-29.7% | $9.7M-7.3% | $10.5M+107.5% | $5.0M-4.4% | $5.3M+32.5% | $4.0M+23.6% | $3.2M |
| Current Liabilities | $6.8M0.0% | $6.8M-29.7% | $9.7M-7.3% | $10.5M+107.5% | $5.0M+434.8% | $943K+19.4% | $789K+17.0% | $675K |
| Long-Term Debt | $3.2M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$2.4M0.0% | -$2.4M+49.1% | -$4.7M-18.3% | -$4.0M+19.8% | -$5.0M-49.3% | -$3.3M-34.3% | -$2.5M-40.9% | -$1.8M |
| Retained Earnings | -$9.1M0.0% | -$9.1M+19.5% | -$11.3M-8.3% | -$10.5M-93.7% | -$5.4M+85.1% | -$36.3M-4.5% | -$34.7M-1.9% | -$34.1M |
PTIX Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.1M-502.8% | -$510K+63.5% | -$1.4M-19.5% | -$1.2M-9.3% | -$1.1M-30.3% | -$820K-341.6% | -$186K+24.7% | -$246K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $943K | $0 | $0-100.0% | $943K | N/A | $0 | $0-100.0% | $1.6M |
| Financing Cash Flow | $4.4M+220377650.0% | -$2+100.0% | -$15K-100.3% | $4.4M+4214.3% | $103K-93.6% | $1.6M+405.4% | $317K-67.1% | $963K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
PTIX Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | 49.9%0.0pp | 49.9%+67.3pp | -17.4%+60.6pp | -78.0%+1538.3pp | -1616.3%-1572.8pp | -43.5%-4.9pp | -38.6%-16.5pp | -22.1% |
| Current Ratio | 0.340.0 | 0.34+0.0 | 0.29-0.1 | 0.41+0.4 | 0.02-2.0 | 2.00+0.2 | 1.80-0.2 | 2.03 |
| Debt-to-Equity | -1.33+1.5 | -2.85-0.8 | -2.06+0.6 | -2.63-1.6 | -1.02+0.6 | -1.59+0.0 | -1.61+0.2 | -1.84 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$3.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Frequently Asked Questions
What is Protagenic Therapeutics Inc's annual revenue?
Protagenic Therapeutics Inc (PTIX) reported $0 in total revenue for fiscal year 2024. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Protagenic Therapeutics Inc profitable?
No, Protagenic Therapeutics Inc (PTIX) reported a net income of -$5.5M in fiscal year 2024.
What is Protagenic Therapeutics Inc's EBITDA?
Protagenic Therapeutics Inc (PTIX) had EBITDA of -$5.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Protagenic Therapeutics Inc's operating cash flow?
Protagenic Therapeutics Inc (PTIX) generated -$4.2M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Protagenic Therapeutics Inc's total assets?
Protagenic Therapeutics Inc (PTIX) had $2.0M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Protagenic Therapeutics Inc spend on research and development?
Protagenic Therapeutics Inc (PTIX) invested $3.8M in research and development during fiscal year 2024.
What is Protagenic Therapeutics Inc's current ratio?
Protagenic Therapeutics Inc (PTIX) had a current ratio of 2.00 as of fiscal year 2024, which is generally considered healthy.
What is Protagenic Therapeutics Inc's debt-to-equity ratio?
Protagenic Therapeutics Inc (PTIX) had a debt-to-equity ratio of -1.59 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Protagenic Therapeutics Inc's return on assets (ROA)?
Protagenic Therapeutics Inc (PTIX) had a return on assets of -282.5% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Protagenic Therapeutics Inc's cash runway?
Based on fiscal year 2024 data, Protagenic Therapeutics Inc (PTIX) had $80K in cash against an annual operating cash burn of $4.2M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Protagenic Therapeutics Inc's debt-to-equity ratio negative or unusual?
Protagenic Therapeutics Inc (PTIX) has negative shareholder equity of -$3.3M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Protagenic Therapeutics Inc's Piotroski F-Score?
Protagenic Therapeutics Inc (PTIX) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Protagenic Therapeutics Inc's earnings high quality?
Protagenic Therapeutics Inc (PTIX) has an earnings quality ratio of 0.76x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.